Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Pembrolizumab (Primary) ; Ipilimumab; Nivolumab
- Indications Lung cancer; Malignant melanoma; Solid tumours
- Focus Therapeutic Use
- 30 Apr 2021 New trial record